Raymond James Financial Inc. bought a new stake in Phreesia, Inc. (NYSE:PHR - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 15,056 shares of the company's stock, valued at approximately $379,000.
A number of other hedge funds have also recently added to or reduced their stakes in the business. ExodusPoint Capital Management LP grew its stake in Phreesia by 448.6% during the 4th quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company's stock valued at $4,402,000 after purchasing an additional 143,077 shares in the last quarter. Norges Bank bought a new stake in shares of Phreesia during the 4th quarter worth $2,804,000. Nicholas Company Inc. acquired a new stake in shares of Phreesia in the fourth quarter worth $2,452,000. JPMorgan Chase & Co. grew its holdings in shares of Phreesia by 144.2% during the 4th quarter. JPMorgan Chase & Co. now owns 145,716 shares of the company's stock valued at $3,666,000 after acquiring an additional 86,040 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Phreesia by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,823,110 shares of the company's stock valued at $121,349,000 after acquiring an additional 61,048 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Phreesia
In related news, CFO Balaji Gandhi sold 28,759 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $30.00, for a total transaction of $862,770.00. Following the sale, the chief financial officer now owns 116,174 shares in the company, valued at $3,485,220. This represents a 19.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Evan Roberts sold 3,519 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $30.06, for a total transaction of $105,781.14. Following the completion of the sale, the chief operating officer now directly owns 741,197 shares of the company's stock, valued at $22,280,381.82. The trade was a 0.47% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 111,640 shares of company stock worth $3,094,167. 5.80% of the stock is owned by corporate insiders.
Phreesia Stock Performance
Shares of NYSE PHR traded up $0.13 during trading hours on Wednesday, reaching $26.23. The stock had a trading volume of 477,688 shares, compared to its average volume of 435,645. The firm has a 50-day moving average of $25.12 and a 200-day moving average of $24.83. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -17.84 and a beta of 0.74.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. DA Davidson reduced their price objective on Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, April 14th. KeyCorp cut their price objective on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. Needham & Company LLC restated a "buy" rating and issued a $29.00 price target on shares of Phreesia in a research note on Thursday, March 13th. Piper Sandler reiterated an "overweight" rating and issued a $33.00 price objective (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group boosted their price target on Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $31.33.
Read Our Latest Analysis on PHR
Phreesia Company Profile
(
Free Report)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Stories
Before you consider Phreesia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.
While Phreesia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
